Novel Strategies for Pancreatic Cancer Treatment

胰腺癌（PaCa）由于缺乏有效的药物治疗，生存率很低。该项目将 通过开发基于PaCa的药物治疗的新治疗策略来解决这一障碍 在靶向新鉴定的分子作为维持PaCa细胞存活的靶标时， 新兴的新药。我们将在生长在大肠杆菌中的人类胰腺癌细胞中测试这些新兴药物。 免疫抑制小鼠，以证明为免疫抑制小鼠定制的有效组合策略的可行性。 可以分别开发PaCa的Smad 4野生型（WT）和突变型（MT）亚组。的战略 基于对细胞存活机制的描述，其中促存活蛋白复合物由以下组成 存活素和XIAP的结合抑制了通常会杀死正在经历癌症的癌细胞的刽子手半胱天冬酶。 癌症微环境的压力。我们的实验室已经发现Smad 4的突变 导致一种叫做RonK的细胞表面蛋白的过度产生，反过来又激活了 修饰存活素/XIAP复合物以增强其稳定性并由此抑制 半胱天冬酶更有效。因此，Smad 4 MT亚组的策略的一个臂（约 50%的PaCa）将是新开发的一种抑制Met家族酪氨酸激酶受体RonK的药物。 来自Imclone的单克隆抗体（IMC-Ron 8）。治疗将与YM 155相结合，YM 155是同类产品中的第一种 生存素的抑制剂，其已显示破坏生存素/XIAP复合物的稳定， 允许半胱天冬酶在产生细胞死亡中的功能。第二个亚组是Smad 4 WT， 代表疾病的另一半，将通过利用Smad 4的策略来解决 使用一种药物，导致肿瘤抑制基因的重新表达，称为TGF受体II。的 药物贝利司他是一种组蛋白脱乙酰酶抑制剂，可逆转表观遗传信号通路， 生存素和XIAP。Smad 4 WT亚组也将与YM 155组合治疗，以直接 攻击survivin的表达。两种策略都将在免疫抑制小鼠中进行测试， 癌症异种移植物，以便了解如何最好地将这些药物施用给胰腺癌患者。

Pancreatic cancer (PaCa) carries a poor survival due to lack of effective drug treatment. This project will address this barrier through the development of new therapeutic strategies for drug treatment of PaCa based upon the targeting of newly identified molecules as targets for maintaining the survival of PaCa cells using emerging novel drugs. We will test these emerging drugs in human pancreatic cancer cells grown in immunosuppressed mice to demonstrate the feasibility that effective combination strategies tailored for the Smad4 wild type (WT) and mutant (MT) subgroups of PaCa, respectively, can be developed. The strategies are based upon description of a cell survival mechanism in which a pro-survival protein complex consisting of survivin and XIAP inhibits the executioner caspase enzymes that would normally kill cancer cells undergoing the stress of the cancer micro-environment. Our laboratory has found that the mutation of Smad4 leads to the overproduction of a cell surface protein called RonK that in turn generates the activation of enzymes that modify the survivin/XIAP complex to enhance its stability and thereby make the inhibition of caspases more efficient. Consequently, one arm of the strategy for the Smad4 MT subgroup (approximately 50% of PaCa) will be the inhibition of the Met family tyrosine kinase receptor RonK by a newly developed monoclonal antibody from Imclone (IMC-Ron8). Treatment will be coupled with YM155, a first-in-its-class inhibitor of survivin, which has been shown to disrupt the stabilization of survivin/XIAP complexes that then permits the function of caspases in generating cell death. The second subgroup is Smad4 WT, which represents the other half of the disease, will be addressed by a strategy that takes advantage of Smad4 function using a drug that cause re-expression of a tumor suppressor gene called TGF¿ receptor II. The drug, Belinostat, a histone deacetylase inhibitor reverses the epigenetic signaling pathway that stabilizes both survivin and XIAP. The Smad4 WT subgroup will also be treated in combination with YM155 to directly attack the expression of survivin. Both strategies will be tested in immunosuppressed mice using pancreatic cancer xenografts in order to learn how best to administrate these drugs to pancreatic cancer patients.